Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Panbela Therapeutics, Inc. PBLA
$0.36
-$0.02 (-5.23%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
5755163.00000000
-
week52high
73.52
-
week52low
0.32
-
Revenue
-1638000
-
P/E TTM
0
-
Beta
0.92179900
-
EPS
-55.66000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | 28 июн 2021 г. | |
| Maxim Group | Buy | 10 мар 2021 г. | |
| Maxim Group | Hold | Buy | 12 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Horvath Susan | A | 8888 | 8888 | 30 янв 2023 г. |
| Horvath Susan | A | 17880 | 4444 | 30 янв 2023 г. |
| Simpson Jennifer K. | A | 8888 | 8888 | 30 янв 2023 г. |
| Simpson Jennifer K. | A | 7868 | 4444 | 30 янв 2023 г. |
| Cullen Michael T. | A | 247000 | 247000 | 04 окт 2022 г. |
| Cullen Michael T. | A | 369576 | 165000 | 04 окт 2022 г. |
| Jacob Jeffrey E. | A | 49500 | 49500 | 04 окт 2022 г. |
| Jacob Jeffrey E. | A | 294931 | 33000 | 04 окт 2022 г. |
| Schemel Donald Robert | A | 300000 | 300000 | 04 окт 2022 г. |
| Schemel Donald Robert | A | 482654 | 200000 | 04 окт 2022 г. |
Новостная лента
Panbela Therapeutics, Inc. (PBLA) Q3 2022 Earnings CallTranscripts
Seeking Alpha
13 ноя 2022 г. в 19:41
Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - CEO Susan Horvath - CFO Conference Call Participants Tony Butler - ROTH Capital Operator Good day, and welcome to the Panbela Therapeutics Third Quarter 2022 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, James Carbonara.
Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results
GlobeNewsWire
31 окт 2022 г. в 09:00
MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA ), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 10, 2022, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2022.
Panbela Therapeutics, Inc.'s (PBLA) CEO Jennifer Simpson on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
15 авг 2022 г. в 19:25
Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Tony Butler – ROTH Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results
GlobeNewsWire
01 авг 2022 г. в 16:00
MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 15, 2022, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2022.
Panbela Therapeutics' (PBLA) CEO Jennifer Simpson on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
14 мая 2022 г. в 15:05
Panbela Therapeutics Inc. (NASDAQ:PBLA ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants James Carbonara – Managing Partner-Hayden IR, Inc. Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Robin Garner – Craig-Hallum Tony Butler – Roth Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by.